The case for & against
Bull & Bear analysis
Bearish
Spero Therapeutics, Inc. (NASDAQ: SPRO) is an emerging biopharmaceutical company focused on developing innovative therapies to combat serious infections, specifically targeting complicated urinary tract infections (cUTIs) and non-tuberculous mycobacterial pulmonary disease (NTMPD). With a strong clinical pipeline that includes its lead product, tebupenem HBR, which is positioned as the first oral carbapenem antibiotic specifically for cUTIs, Spero aims to address significant unmet medical needs in the antibiotic space amid growing concerns of antibiotic resistance.
Bull says
- ↑Tebupenem HBR fills oral antibiotic gap for complicated UTIs; potential paradigm shift.
- ↑$63.5M cash covers operations into late 2025 at current burn rate.
- ↑$95M in GSK milestone payments strengthens liquidity runway.
- ↑NTMPD market spans ~245K patients; SPR720 could unlock significant demand.
- ↑High earnings yield, low leverage, strong liquidity indicate financial resilience.
- ↑Oral therapies may cut hospital stays, offering compelling economic benefits.
Bear says
- ↓No Q2’26 revenue vs. $14.2M prior year raises value-trap concerns.
- ↓Q2’26 net loss of $9.6M vs. $1.7M prior year signals worsening profitability.
- ↓Negative growth outlook and downward revisions imply weak momentum.
- ↓Dependence on GSK milestone payments risks funding if trials delay.
- ↓High stock volatility suggests significant price swings, deterring investors.
- ↓Weak dividend prospects and low institutional interest limit shareholder returns.
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 08-16-2026bullish
Transcript signals
Bull points
- we hope our SPR 720 program will deliver the first oral first-line treatment for NTMPD, and we are looking forward to sharing top-line data, which we expect to do in the second half of this year.
- The unmet need is for a treatment that has better tolerability and effectiveness, fewer drug-drug interactions, as well as shorter treatment duration, and we believe that SPR720 will meet these criteria and, if approved, has the potential to establish a new standard of care in anti-MPD.
- We expect to have results from our studies in the second half of this year, providing us with a robust dataset that may inform the registrational path for SPR720 as first-line treatment for NTMPD.
Bear points
- The data may be, or the access may be different with patients that have cavitary MAC versus, I guess, less large cavitary disease. Is that a consideration for oral therapy?
- But the data that we have so far certainly suggests that the drug penetrates to where it needs to get, i.e., the lungs. And, of course, we expect to have data from the bronchoalveolar lavage in the second half of this year only to corroborate what we know from the hollow fiber in vitro data as well as the non-human primate data.
- However, we've always commented that we would continue developing that program contingent on non-diluted sources of funding.
Read full transcript analysis ›